Trivalent Attenuated Cold-Adapted Influenza Virus Vaccine: Reduced Viral Shedding and Serum Antibody Responses in Susceptible Adults

Journal of Infectious Diseases

Volumn 167, Issue 2, 1993, Pages 305-311

  Keitel, Wendy A ^a,b   Couch, Robert B ^a,b   Quarles, John M ^a,b   Cate, Thomas R ^a,b   Baxter, Barbara ^a,b   Maassab, Hunein F ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; EPIDEMIC; HAEMOPHILUS INFLUENZAE TYPE A; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN EXPERIMENT; INFLUENZA VACCINATION; INFLUENZA VIRUS; MORBIDITY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS TRANSMISSION;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, VIRAL; COLD; DOUBLE-BLIND METHOD; HUMAN; IMMUNIZATION; IMMUNIZATION, SECONDARY; INFLUENZA; INFLUENZA A VIRUS, HUMAN; INFLUENZA B VIRUS; INFLUENZA VACCINE; NASAL MUCOSA; SUPPORT, U.S. GOV'T, P.H.S.; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRUS SHEDDING;

EID: 0027523895     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/167.2.305     Document Type: Article

References (19)

1. Lui KJ, Kendal A. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-6.
2. Couch RB, Kasel JA, Glezen WP, et al. Influenza: Its control in persons and populations. J Infect Dis 1986; 153:431-40.
3. Glezen WP, Couch RB, Six HR. The influenza herald wave. Am J Epidemiol 1982;116:589-98.
4. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development ofcold-adapted recombinant live, attenuated influenza A vaccines in the US and USSR. Antiviral Res 1981;1:339-65.
5. Couch RB, Quarles JM, Cate TR, Zahradnik JM. Clinical trials with live cold-reassortant influenza virus vaccines. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R Liss, 1986:223-42.
6. Gruber WE, Taber LH, Glezen WP, et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 1990; 144:595-600.
7. Wright PF, Bhargava M, Johnson PR, Thompson J, Karzon DT. Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes. Vaccine 1985;3:305-8.
8. Keitel WA, Couch RB, Cate TR, Six HR, Baxter BD. Cold recombinant influenza B/Texas/l/84 vaccine virus (CRB 87): Attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis 1989; 161:22-6.
9. Clements ML, Snyder MH, Sears SO, Maassab HF, Murphy BR. Evaluation of the infectivity, immunogenicity, and efficacy of live coldadapted influenza B/Ann Arbor/I/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990; 161:869-77.
10. Frank AL. Puck J, Hughes BJ, Cate TR. Microneutralization tests for influenza Aand Band parainfluenza I and 2 viruses that use continuous cell lines and fresh serum enhancement. J Clin Microbiol 1980; 12:426-32.
11. Heilman C. La Montagne JR. Influenza: Status and prospects for its prevention, therapy, and control. Pediatr Clin North Am 1990;37:669-88.
12. Belshe RB, Swierkosz EM, Anderson EL, Newman FL, Nugent SL, Maassab HF. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A HI NI, H3N2, and B vaccine. J Infect Dis 1992;165:727-32.
13. Spencer MJ, Cherry JD, Powell KR, Sumaya CV. A clinical trial with Alice/R-75 strain, live attenuated serum inhibitor-resistant intranasal bivalent influenza A/B vaccine. Med Microbiol Immunol 1979;167:1-9.
14. Potter CW, Jennings R, Clark A, Ali M. Interference following dual inoculation with influenza A (H3N2) and (H1N1) viruses in ferrets and volunteers. J Med Virol 1983; 11:77-86.
15. Zykov MP, Shaposhnikova RP, Vasileva RI, et al. Search for optimal scheme for administering live allantoic influenza vaccine. J Hyg Epidemiol Microbiol Immunol 1983;27:419-24.
16. Fleet WF, Couch RB, Cate TR, Knight V. Homologous and heterologous resistance to rhinovirus common cold. Am J Epidemiol 1965;82: 185-96.
17. Sears SO, Clements ML, Betts RF, Maassab HF, Murphy BR, Snyder MH. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988; I58: 1209-19.
18. Clements ML, O'Donnell S, Levin MM, Chanock RM, Murphy BR. Dose response to A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: Role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983;40: 1044-51.
19. Clements ML, Betts RF, Maassab HF, Murphy BR. Dose response to influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers. J Infect Dis 1984; 149:814-5.